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rabbit model of cardioplegic arrest
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Objective: Mitochondrial permeability transition pore opening is associated with ap-
optotic signaling and alterations in mitochondrial structure and function. We tested
whether inhibition of mitochondrial permeability transition pore opening with cyclo-
sporine A preserved mitochondrial structure and function after cardioplegic arrest and
whether this preservation is associated with improved myocardial performance.
Methods: Langendorff-perfused neonatal rabbit hearts were perfused for 30 minutes
with Krebs–Henseleit buffer (CCP; n 5 6) or Krebs–Henseleit buffer containing 2
mmol/L of cyclosporine A (CCP1CsA; n5 6) followed by 60 minutes of normother-
mic crystalloid cardioplegia (CCP) and 60 minutes of reperfusion. Control hearts (non-
CCP; n 5 6) were constantly perfused for 150 minutes without cardioplegic arrest.
Results: In comparison with non-CCP, CCP was associated with Bax translocation to
the mitochondria, cytochrome c release, and greater frequency of terminal deoxynu-
cleotidyl transferase–mediated dUTP nick end labeling–positive myocytes These
changes were also associated with deficits in isolated mitochondrial oxygen consump-
tion at complex I. CsA pretreatment minimized or prevented all these findings. Myo-
cardial performance (systolic pressure, maximum positive and negative dP/dt, and
elevated left ventricular end-diastolic pressure) at 5, 15, 30, and 60 minutes after reper-
fusion was diminished in CCP hearts when compared with non-CPB, and these deficits
could be minimized with cyclosporine A pretreatment. (P, .05 all comparisons)
Conclusions: Cyclosporine A prevents apoptosis-related mitochondrial permeabiliza-
tion and dysfunction after cardioplegic arrest. This protection is associated with
improved myocardial performance. Prevention of mitochondrial permeability transi-
tion pore opening is a valuable target for mitochondrial (and myocardial) preservation
after neonatal cardioplegic arrest.
A
s a critical mediator in apoptosis signaling pathways, mitochondria integrate
upstream death stimuli and undergo structural and functional remodeling
with subsequent transmission of signals to downstream executioner
proteins.1 Bax translocation, mitochondrial outer membrane permeabilization, and
cytochrome c release directly participate in mitochondrial architectural and functional
remodeling after unprotected ischemia/reperfusion.2-4 After protected ischemia/reper-
fusion (cardioplegic arrest), we have previously reported a similar constellation of
apoptosis-related alterations in mitochondrial structure and function in the lamb
and piglet myocardium (apoptosis-related mitochondrial dysfunction: ARMD).5-7
We correlated these changes with deficits in mitochondrial electronic transport chain
activity.8,9 Because of the close interplay between apoptotic events and mitochondrial
dysfunction, as well as the role of mitochondrial protection in the maintenance of car-
diac performance,10 we hypothesized that ‘‘mitoprotection’’ conferred by mainte-
nance of outer mitochondrial membrane integrity may be of therapeutic benefit to
reduce ARMD and consequently preserve myocardial performance.
The mitochondrial permeability transition pore (MPTP) is a nonspecific pore
that may mediate alterations in outer mitochondrial membrane integrity.11,12
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CSPAbbreviations and Acronyms
ARMD 5 apoptosis-related
mitochondrial dysfunction
BSA 5 bovine serum albumin
CCP 5 crystalloid cardioplegia
COX IV 5 cytochrome c oxidase IV
CsA 5 cyclosporine A
6dP/dtmax 5 maximum first derivative
of left ventricular pressure
IgG 5 immunoglobulin G
KH 5 Krebs–Henseleit buffer
LV 5 left ventricular
MIB 5 mitochondrial isolation buffer
MPTP 5 mitochondrial permeability
transition pore
TMPD 5 N,N,N’N’-tetramethyl-
p-phenylenediamine
TUNEL 5 terminal deoxynucleotidyl
transferase–mediated
dUTP nick end labeling
Pharmacologic inhibition of MPTP opening is associated
with myocardial protection against unprotected ischemia/re-
perfusion injury.13,14 Cyclosporine A (CsA), a specific inhib-
itor of MPTP opening, acts by inhibiting the peptidyl-prolyl
cis-trans isomerase activity of the cyclophilin-D component
of the MPTP and has been reported to ameliorate reperfusion
injury in a variety of in vitro15,16 and in vivo17 animal models
of unprotected and protected ischemia.7,18
We7 have previously reported that CsA-mediated MPTP
pore inhibition prevents ARMD in a neonatal piglet model.
This report extends these observations in a neonatal rabbit
model and relates amelioration of ARMD to preservation
of global myocardial performance.
Methods and Materials
Experimental Model
New Zealand White neonatal rabbits (5–6 days; 150–250 g) were
anesthetized with sodium pentobarbital (50 mg/kg intraperitone-
ally), heparinized (1000 U/kg intraperitoneally), and ventilated.
The heart was retrogradely perfused in situ to avoid ischemia,
excised, mounted on a Langendorff perfusion system, and perfused
at 75 mm Hg with Krebs-Henseleit buffer (KH) equilibrated with
95% oxygen and 5% carbon dioxide (pH of 7.35–7.40).
All animals received humane care in compliance with the
‘‘Guide for the Care and Use of Laboratory Animals’’ prepared by
the Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC; March 1999).
Experimental Protocol
Two groups of hearts were perfused for a 30-minute stabilization
period followed by 60 minutes of crystalloid cardioplegic arrest
(CCP) and 60 minutes of reperfusion. During the stabilization
period, cyclosporine A (CsA)–treated hearts (CCP1CsA group,
n 5 6) were perfused with KH in which CsA (0.2 mmol/L) was586 The Journal of Thoracic and Cardiovascular Surgery c Maadded to the KH. Nontreated hearts (CCP, n 5 6) were stabilized
with KH perfusion alone. Cardioplegic arrest for both groups was
induced with crystalloid cardioplegia (65 mL/kg, Plegisol; Hospira,
Inc, Lake Forest, Ill) at normothermia.19 CsA was dissolved in
dimethylsulfoxide (Fisher Scientific, Waltham, Mass), which was
further dissolved into KH at a final concentration of 0.05%. The
same amount of dimethylsulfoxide was added into the KH for all
other groups.
A third group of hearts underwent uninterrupted perfusion (non-
CCP, n 5 6) for 150 minutes.
At the end of reperfusion, the hearts were rapidly excised. For
mitochondrial oxygen consumption and mitochondrial protein
extraction, myocardium was fractionated as described.8
A separate set of animals (n5 4 for each group) underwent iden-
tical procedures after which the left ventricles were sliced and
embedded in OCT compound (IMEB, Inc, San Marcos, Calif),
snap frozen in liquid nitrogen, and stored at 280C for apoptosis
and fluorescence immunohistochemistry.
Cardiac Functional Measurements
Isovolumetric measurement of left ventricular (LV) performance
was made with a water-filled balloon connected to a pressure trans-
ducer (MLT844; ADInstruments, Colorado Springs, Colo) and
inserted into the left ventricle across the mitral valve. The volume
of the water-filled balloon was adjusted to an end-diastolic pressure
of 0 to 5 mm Hg and kept constant throughout the entire experiment.
LV performance was assessed with LV systolic pressure, LV end-
diastolic pressure, LV developed pressure, and maximum positive
and negative derivative of LV pressure (6dP/dtmax). Analog data
(heart rate and LV systolic pressure, developed pressure, end-
diastolic pressure, and 6dP/dtmax) were digitalized and analyzed
(Chart IV; ADInstruments, Colorado Springs, Colo). Hemodynamic
data were compared at comparable time points in all three groups.
Mitochondrial Isolation
The left ventricle was used for mitochondrial isolation by differential
centrifugation.20 The whole left ventricle (0.7 g) was placed into 5
mL of mitochondrial isolation buffer (MIB) on ice (5 mmol/L
MOPS, 2 mmol/L ethylene glycol bis-2-aminoethyl ether-
N,N’,N’’,n’-tetraacetic acid, 70 mmol/L sucrose, 220 mmol/L
mannitol, 1 mmol/L dithiothreitol, 17 mg/mL phenylmethylsulfonyl
fluoride, 8 mg/mL aproptinin, and 2 mg/mL leupeptin, pH 7.2) with
0.1% bovine serum albumin (BSA) and finely minced. Tissue was
homogenized on ice by a blade homogenizer and centrifuged
(700g 3 5 minutes). The supernatant was transferred to a new
tube and the same low spin repeated four times (5 minutes each) until
no visible pellet was seen. The supernatant from the low spins was
centrifuged (8000g 3 10 minutes). The pellet was resuspended in
10 mL MIB with 0.1% BSA and centrifuged for another 10 minutes
(8000g). The final pellet was suspended in MIB buffer without BSA
for mitochondrial oxygen consumption measurements.
Clark-electrode Oxygen Consumption Measurement
Mitochondrial complex I, II, and IV respiration was measured with
a Clark-type oxygen electrode (Instech Laboratories Inc, Plymouth
Meeting, Pa). Oxygen consumption was measured in the presence of
sequential administration of substrates and inhibitors (glutamate/
malate for complex I, rotenone/succinate for complex II,rch 2008
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Pantimycin/TMPD/ascorbate for complex IV) added in the following
order and final concentration: 2.5 mmol/L glutamate, 2.5 mmol/L
malate, 2 mmol/L adenosine diphosphate, 2 mmol/L rotenone, 5
mmol/L succinate, 1 mmol/L antimycin A, and 1 mmol/L ascorbate
with 0.4 mmol/L N,N,N’N’-tetramethyl-p-phenylenediamine
(TMPD). Respiration rates are expressed as micromoles of oxygen
per minute per milligram of mitochondrial protein.
Mitochondrial Bax Translocation
Mitochondrial pellets were lysed in a hypotonic buffer (250 mmol/L
sucrose, 20 mmol/L HEPES, 10 mmol/L KCl, 1.5 MgCl2, 1 mmol/L
ethylenediaminetetraacetic acid, 1 mmol/L ethyleneglycol-bis-
Figure 1. A, Representative Western blot of mitochondrial Bax in
non-CCP, CCP, and CCP1CsA myocardium. B, Densitometric mea-
surements of Bax in non-CCP, CCP, and CCP1CsA hearts. In-
creased concentrations of Bax (homodimer) in the mitochondrial
fractions normalized by porin content are indicative of transloca-
tion of Bax to the mitochondria. *P< .01 versus non-CCP; yP< .05
versus CCP. CCP, Crystalloid cardioplegia; CsA, cyclosporine A;
MW, molecular weight; AU, arbitrary units.The Journal of Thor(b-aminoethylether)-N,N,N0tetraacetic acid, 1 mmol/Lphenylme-
thylsulfonyl fluoride, 8 mg/mL aproptinin, and 2 mg/mL leupeptin
[pH 7.4]). After incubation for 30 minutes, the suspension was son-
icated and recentrifuged (13,000g 3 30 minutes). The soluble pro-
teins were used for measurement of Bax translocation by Western
blot. Membranes were probed with anti-rabbit Bax (N-20, 1:1000;
Santa Cruz Biotechnology, Inc, Santa Cruz, Calif). For protein load-
ing control, the membranes were stripped and reprobed with anti-
mouse mitochondrial porin (1:20,000; Molecular Probes, Inc, Eu-
gene, Ore). Secondary antibodies were coupled to horseradish per-
oxidase (anti-rabbit immunoglobulin G [IgG] 1:1000; anti-mouse
IgG 1:10,000; Santa Cruz Biotechnology).
Fluorescent Immunohistochemistry and
Confocal Imaging
OCT-embedded transverse ventricular slices were cut into 5-mm
serial sections, fixed in acetone, and blocked. Mouse monoclonal
anti-cytochrome c oxidase IV (COX IV) (1:250; BD Biosciences
Clontech, Palo Alto, Calif) was used. Sections were incubated
with secondary antibody (Cy3-conjugated donkey anti-mouse
IgG, 1:500; Jackson ImmunoResearch Laboratories, Inc, West
Grove, Pa). Mouse monoclonal anti-cytochrome c (1:200; BD
Biosciences Pharmingen, San Diego, Calif) was used as the primary
antibody for cytochrome c staining. Sections were immersed in
secondary antibody (Cy2-conjugated donkey anti-mouse IgG,
1:200; Jackson ImmunoResearch Laboratories).
Images from at least three different sections were acquired at
643 by a Zeiss LSM510 Multiphoton Laser Scanning Confocal
Microscope (Carl Zeiss, Jena, Germany) with the same pinhole
setting, pixel format (1024 31024), and scanning data depth (0.8
mm). Double fluorescence for green and red channels was imaged
by excitation of argon-HeNe1 at wavelengths of 488 and 530 nm.
Fifty high-power fields from each animal were analyzed by imaging
processing software (Volocity 3.0; Improvision, Lexington, Mass).
High intensity of red and green (above 551 voxels) was regarded as
specific immunoreactive signals. The red (COX IV) was set as
reference signal and the contribution of the green (cytochrome c)
to the colocalization of the both signals was quantified as the overlap
coefficient (Kx-green) and used to compare the diffusion of cyto-
chrome c staining between groups.21
Terminal Deoxynucleotidyl Transferase–mediated
dUTP Nick End Labeling (TUNEL) Staining
OCT-embedded transverse ventricular slices were cut into 5-mm
serial sections. TUNEL staining was performed with the In Situ
Cell Death Detection Kit (Roche Diagnostics, Indianapolis, Ind) ac-
cording to the manufacturer’s instructions. After TUNEL, all nuclei
were counterstained with 4,6-diamino-2-phenylindole. TUNEL-
positive myocytes and the number of total myocytes were counted
in 50 random high-power fields (3600) with a Leica (Deerfield,
Ill) fluorescent microscope and OpenLab software (Improvision,
Lexington, Mass). Approximately 10,000 myocytes were examined
from at least three different slices from each animal.
Statistics
Data are expressed as mean 6 SEM and group comparisons made
with the Fisher least significant difference analysis of variance. A
Tukey test was used for multiple post hoc comparisons.acic and Cardiovascular Surgery c Volume 135, Number 3 587
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CSPFigure 2. A, Immunofluorescence of cytochrome c oxidase IV (COX IV) and cytochrome c in the myocardium from
non-CCP, CCP, and CCP1CsA myocardium. In each panel, COX IV (mitochondria) is stained red, cytochrome c is
stained green, and the merged mages are shown. Superimposition of red and green staining results in a brownish
color that suggests retention of cytochrome c in the non-CCP and CCP1CsAmitochondria. A fine diffuse green stain-
ing can be seen in the merged images of CCP myocardium, suggesting mitochondrial release of cytochrome c. Scat-
terplots display the distribution of red and green voxels in the merge images of non-CCP, CCP, and CCP1CsA, as well
as the various degrees of colocalization as shown in orange and yellow. B, Quantification of the overlap coefficient
(Kx-green) in the merge images for non-CCP, CCP, and CCP1CsA groups is shown. *P< .01 versus non-CCP; #P< .01
versus CCP. For abbreviations, see Figure 1.Results
Mitochondrial Bax Translocation
CCP was associated with Bax translocation to the mitochon-
dria (homodimer) in the mitochondrial protein fraction when
compared with the non-CCP myocardium (1.60 6 0.02 vs
1.43 6 0.30 arbitrary units, P , .01). Bax translocation
was reduced after CsA treatment (1.476 0.04 arbitrary units;
P , .05 vs CCP) to the levels that were similar to non-CCP
(Figure 1).588 The Journal of Thoracic and Cardiovascular Surgery c MarMitochondrial Permeabilization and Cytochrome c
Release
Fluorescence immunohistochemistry was used to compare
patterns of cytochrome c and COX IV staining (Figure 2).
Release of cytochrome c from the mitochondria causes diffu-
sion of the cytochrome c staining in the cytoplasm and a stip-
pled green pattern is produced. This pattern is prominent in
the merged images from the CCP myocardium, whereas in
non-CCP and CCP1CsA myocardium, only faint diffusionch 2008
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PFigure 3. Representative imaging of TUNEL
staining. A, TUNEL-positive nuclei (green),
which are indicated by white arrows. B,
Nuclei 4,6-diamino-2-phenylindole stain-
ing (blue). C, A merged picture of A and B.
D, Quantitative analysis of TUNEL staining
for non-CCP, CCP, and CCP1CsA myocar-
dium. *P < .01 versus non-CPB; yP < .05
versus CCP. For abbreviations, see Figure 1.of cytochrome c staining in the merged images was found.
The contribution of the green color intensity to the colocali-
zation of these color voxels in the merged images was quan-
tified by overlap coefficients (Kx-green). Compared with
non-CCP and CCP1CsA myocardium, lower overlap coeffi-
cient (Kx-green) was found in CCP myocardium (P , .01).
TUNEL Staining
TUNEL-positive nuclei were more frequent in CCP myocar-
dium than in non-CCP and CCP1CsA myocardium (22.56
4.5 vs 3.0 6 1.3 and 4.0 6 2.2 per 10,000 nuclei; P , .01)
(Figure 3). There was no difference between non-CCP and
CCP1CsA groups (P 5 .82).
Clark-electrode Oxygen Consumption Measurements
Isolated mitochondrial oxygen consumption was assessed
during state 2 respiration for mitochondrial complexes I, II,
and IV and was not different among groups, suggesting
comparable levels of mitochondrial integrity after fraction-
ation. Cardioplegic arrest was associated with diminished
state 3 respiration, and the decrement of state 3 and the ratio
of state 3 to state 2 was prevented by pretreatment with
CsA (P, .01) (Figure 4 and Table 1). Complex II and com-
plex IV oxygen consumption rates were not different between
groups.The Journal of ThorMyocardial Performance
There was no significant different change in heart rate among
non-CCP, CCP, and CCP1CsA. LV developed systolic
pressure and 6dP/dtmax were significantly depressed at 5,
15, 30, and 60 minutes of reperfusion in the CCP hearts
(compared with non-CCP). LV end-diastolic pressure was
significantly increased in CCP when compared with non-
CCP. In contrast, administration of CsA improved all these
parameters (Table 2 and Figure 5).
Discussion
A typical pathologic change in the postischemic myocardium
after cardioplegic arrest is manifest by a constellation of ap-
optotic events19 and apoptosis-related alterations in mito-
chondrial structure and function including Bax
translocation, mitochondrial permeabilization, cytochrome
c release, and deficits in mitochondrial electron transport.8,9
We have previously defined this constellation of events as
ARMD. The current study demonstrates that pretreatment
with CsA, an MPTP inhibitor, prevents ARMD and this pre-
vention is associated with preservation of global myocardial
performance.
The etiology of mitochondrial permeabilization during
apoptosis is not fully determined. Bax translocation, how-
ever, is associated with disruption of outer mitochondrialacic and Cardiovascular Surgery c Volume 135, Number 3 589
Cardiopulmonary Support and Physiology Oka et al
CSPFigure 4. A, The representative traces
of real-time mitochondrial oxygen con-
sumption including complexes I, II,
and IV from non-CCP, CCP, and
CCP1CsA myocardium. B, Comparison
of the activity of state 3 and the ratio
of state 3 to state 2 of complexes I, II,
and IV among the groups. *P < .01 ver-
sus non-CCP; #P < .01 versus CCP.
ADP, Adenosine diphosphate. For other
abbreviations, see Figure 1.membrane integrity and cytochrome c release into the
cytoplasm. The mechanism by which Bax induces the per-
meabilization is not clearly defined, and it may act through
direct pore-forming capacity22 or through direct interaction
with the MPTP.23 Alternatively, transient MPTP opening
may act as an initial event to stimulate Bax translocation
to the mitochondria24 and, through a positive feedback
loop between Bax and the MPTP, stimulate further perme-
abilization and cytochrome c release.25 In the present study,590 The Journal of Thoracic and Cardiovascular Surgery c MarCsA prevented Bax translocation, suggesting that MPTP
opening is an ‘‘upstream’’ signaling event that is required
for Bax translocation and subsequent mitochondrial
permeabilization.
Cytochrome c is an important component of mitochon-
drial oxidative phosphorylation. A relative deficiency of
mitochondrial cytochrome c, as may occur after mitochon-
drial permeabilization, may be responsible for deficits in
mitochondrial respiration.2 The immunohistochemistry dataTABLE 1. Isolated mitochondrial oxygen consumption (mmol oxygen $min21 $mg21 protein) of non-CCP, CCP, and CCP1CsA
mitochondria
Complex I Complex II Complex IV
Non-CCP CCP CCP1CsA Non-CCP CCP CCP1CsA Non-CCP CCP CCP1CsA
State 2 0.52 6 0.05 0.51 6 0.05 0.49 6 0.02 0.52 6 0.05 0.51 6 0.05 0.49 6 0.02 0.52 6 0.05 0.51 6 0.05 0.49 6 0.02
State 3 6.21 6 1.21 2.00 6 0.28* 5.64 6 0.82y 3.05 6 0.38 2.52 6 0.19 2.77 6 0.30 9.53 6 0.47 9.39 6 0.66 10.42 6 0.81
Ratio 3/2 11.65 6 1.15 4.08 6 0.68* 11.48 6 1.62y 5.93 6 0.45 5.29 6 0.76 5.62 6 0.54 19.06 6 1.24 19.07 6 1.32 21.24 6 1.62
CCP, Cardioplegic arrest; CsA, cyclosporine A. *P , .01 versus non-CCP; yP , .01 versus CCP.ch 2008
Oka et al Cardiopulmonary Support and PhysiologyTABLE 2. Hemodynamics in non-CCP, CCP, and CCP1CsA treated hearts
Reperfused
Baseline 15 minutes 30 minutes 60 minutes
Variables Non-CCP CCP CCP1CsA Non-CCP CCP CCP1CsA Non-CCP CCP CCP1CsA Non-CCP CCP CCP1CsA
HR (beats/min) 210 6 6 230 6 7 213 6 6 190 6 12 230 6 8 203 6 8 180 6 11 236 6 9 203 6 8 183 6 1 230 6 6 196 6 8
LVDP (D%) 100 100 100 97 6 1 80 6 1* 90 6 3y 95 6 1 84 6 0.7* 95 6 1.2y 95 6 1 77 6 1* 94 6 2y
LVEDP (mm Hg) 3.0 6 0.2 3.1 6 0.0 2.9 6 0.1 3.1 6 0.3 17 6 1.8* 6.7 6 0.9y 3.0 6 0.2 11.7 6 1.6* 3.6 6 0.2y 3.2 6 0.3 11.4 6 1.1* 3.2 6 0.3y
1dP/dtmax (D%) 100 100 100 95 6 0.9 73 6 2.6* 86 6 3.7*y 95 6 1.1 80 6 3.3* 94 6 1.8y 94 6 1.6 74 6 3.4* 92 6 2.3y
2dP/dtmax (D%) 100 100 100 95 6 1.2 63 6 2.2* 81 6 2.7*y 94 6 1.3 73 6 3.1* 90 6 1.4y 93 6 1.0 73 6 2.5* 93 6 1.5y
CCP, Cardioplegic arrest; CsA, cyclosporine A; HR, heart rate; LVDP, left ventricular developed pressure; LVEDP, left ventricular end-diastolic pressure; dP/dt,
first derivative of left ventricular pressure. Values are mean 6 SEM; n 5 6 each group. *P , .01 versus non-CCP. yP , .01 versus CCP.in the current study are consistent with diffusion of cyto-
chrome c from the mitochondria into the cytosol owing to
permeabilization of the outer mitochondrial membrane.
Cytochrome c release from mitochondria inhibits mitochon-
drial respiration owing to limitation of electron transport to
cytochrome c oxygenase,26 and cytochrome c release, in
turn, stimulates mitochondrial superoxide formation that
may amplify the deficits in electron transport chain activity.27The Journal of ThoIn addition to these upstream apoptotic signals, Ricci, Got-
tlieb, and Grier28 reported that caspase 3, a ‘‘downstream’’
protease activated by cytochrome c release, can directly
inhibit electron transport chain activity. In the present study,
the prevention of mitochondrial permeabilization with CsA
was associated with preservation of mitochondrial function
at complex I, suggesting that loss of reducing equivalents
(cytochrome c) or direct inhibition of electron transport canCS
PFigure 5. A, The representative traces of condensed real-time blood pressure (systolic and diastolic pressure) and
first derivatives of left ventricular pressure (6dP/dt) from non-CCP, CCP, and CCP1CsA groups. B, The changes
of systolic pressure, maximum 6dP/dt, and the diastolic pressure at 5, 15, 30, and 60 minutes of reperfusion.
*P < .01 versus non-CCP; #P < .01 versus CCP. For abbreviations, see Figure 1.racic and Cardiovascular Surgery c Volume 135, Number 3 591
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membrane integrity.
Other investigators have demonstrated that inhibition of
mitochondrial dysfunction results in the preservation of myo-
cardial function.29,30 Specific inhibition of the MPTP by CsA
improves recovery of cardiac function and is associated with
reduction of cell death in a variety of in vivo and in vitro
ischemia/reperfusion models.17,30 Therefore, a rationale is
provided for a myopreservation strategy focused on mainte-
nance of mitochondrial structural and functional integ-
rity17,31 In the current study, cardioplegic arrest induced
conspicuous apoptosis-related alterations in mitochondrial
structure and function, and these changes were correlated
with myocardial dysfunction. Pretreatment with CsA pre-
vents both ARMD and myocardial dysfunction, supporting
a causal relationship between ARMD and global myocardial
dysfunction.
Evidence for completion of apoptosis is supported by the
increased prevalence of TUNEL-positive nuclei after cardio-
plegic arrest and abrogation of this finding with cyclosporine.
It is important, however, to recognize that positive TUNEL
staining is not restricted to apoptotic nuclei and false positive
results can occur after stimuli that promote DNA injury (eg,
necrosis). We5,6 have previously demonstrated that cardio-
plegic arrest is associated with DNA laddering, cleavage of
caspase 3, and absence of necrosis, which supports the rela-
tionship between TUNEL positivity and apoptosis in the
current model.
Conclusions
Inhibition of MPTP opening with CsA prevents ARMD and
preserves cardiac global performance after cardioplegic
arrest. Better understanding of the interaction between apo-
ptotic signals and ARMD and the correlation of ARMD
with myocardial dysfunction will enhance myopreservative
strategies for the cardiac surgeon.
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